Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy

Journal of Clinical Apheresis

Volumn 24, Issue 3, 2009, Pages 115-119

  Park, Yara A ^a   Hay, Shauna N ^a   King, Karen E ^b   Matevosyan, Karen ^c   Poisson, Jessica ^a   Powers, Amy ^d   Sarode, Ravindra ^c   Shaz, Beth ^e   Brecher, Mark E ^a,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

ADAMTS13; Microangiopathy; Plasma exchange; Quinine; TTP

Indexed keywords

D DIMER; QUININE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIALYSIS; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; LEG CRAMP; PLASMAPHERESIS; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; KIDNEY FAILURE; MIDDLE AGED; MUSCLE CRAMP; MUSCLE RELAXANTS, CENTRAL; PLASMA EXCHANGE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUININE; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 67449128694     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20194     Document Type: Article

References (33)

1. Kaufman DW, Kelly JP, Johannes GB, Sandler A, Harmon D, Stolley PD, Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993;82:2714-2718.
2. Brain MC, Dacie JV, Hourihane DO. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Hematol 1962;8:358-374.
3. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-1081.
4. Liapis H. Thrombotic microangiopathy involving the kidney: a histopathologic perspective. Hippokratia 2003;7:152-158.
5. Laszik Z, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and systemic sclerosis (systemic scleroderma). In: Jennett JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's Pathology of the Kidney, 5th ed. Philadelphia: Lippencott-Raven. 1998. Vol. II, pp 1003-1057.
6. Brecher ME. How I approach a thrombotic thrombocytopenia purpura patient. Transfusion 2006;46:687-689.
7. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-397.
8. Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998;13:133-141.
9. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
10. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1593.
11. Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005;3:1663-1675.
12. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001;98:1842-1846.
13. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-2735.
14. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
15. Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992;80:241-248.
16. Gottschall JL, Neahring B, McFarland JG, Wu GG, Weitekamp LA, Aster RH. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994;47: 283-289.
17. Christie DJ, Mullen PC, Aster RH. Quinine and quinidine platelet antibodies can react with GPIIb/IIIa. Br J Haematol 1987;67: 213-219.
18. Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;36:2-6.
19. Pfueller SL, Bilston RA, Jane S, Gibson J. Expression of the drug-dependent antigen for quinine-dependent antiplatelet antibodies on GP IIIa but not that on GPIb, IIb or IX on human endothelial cells. Thromb Haemost 1990;12:279-281.
20. Glynne P, Salama A, Chaudhry A, Swirsky D, Lightstone L. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am J Kidney Dis 1999;33:133-137.
21. Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 2008;111:1234-1239.
22. Hou M, Horney E, Stockelberg D, Jacobsson S, Kutti J, Wadenvik H. Multiple quinine-dependent antibodies in a patient with episodic thrombocytopenia, neutropenia, lymphocytopenia, and granulomatous hepatitis. Blood 1997;90:4806-4811.
23. Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991;77:2668-2676.
24. Asvadi P, Ahmadi Z, Chong BH. Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 2003;102:1670-1677.
25. Chong BH, Du XP, Berndt MC, Horn S, Chesterman CN. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991;77:2190-2199.
26. Stroncek DF, Herr GP. The chemical and immunoglobulin structural features necessary for reactions of quinine-dependent antibodies to neutrophils. Transfusion 1995;35:247-253.
27. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, Gilcher RO. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000;40:896-901.
28. McMinn JR, Thomas IR, Terrell DR. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 2003;43:415.
29. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001;16:134-138.
30. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher 2002;17:207-211.
31. Ahrens N, Schewior L, Garbe E, Kiesewetter H, Salama A. Massive haemolysis after intramuscular diclofenac in a patient who apparently tolerated oral medication. Vox Sang 2004;86: 71-74.
32. Sabto JK, Pierce RM, West RH, Gurr FW. Hemodialysis, peritoneal dialysis, plasmapheresis and forced diuresis for the treatment of quinine overdose. Clin Nephrol 1981;5:264-268.
33. Bateman DN, Blain PG, Woodhouse KW, Rawlins MD, Dyson H, Heyworth R, Prescott LF, Proudfoot AT. Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med 1985;54: 125-131.